These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
427 related articles for article (PubMed ID: 21855613)
1. Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system. Brossier NM; Carroll SL Brain Res Bull; 2012 May; 88(1):58-71. PubMed ID: 21855613 [TBL] [Abstract][Full Text] [Related]
2. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323 [TBL] [Abstract][Full Text] [Related]
4. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Perry A; Roth KA; Banerjee R; Fuller CE; Gutmann DH Am J Pathol; 2001 Jul; 159(1):57-61. PubMed ID: 11438454 [TBL] [Abstract][Full Text] [Related]
5. The role of nerve microenvironment for neurofibroma development. Liao CP; Pradhan S; Chen Z; Patel AJ; Booker RC; Le LQ Oncotarget; 2016 Sep; 7(38):61500-61508. PubMed ID: 27517146 [TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling. Carroll SL; Stonecypher MS J Neuropathol Exp Neurol; 2005 Jan; 64(1):1-9. PubMed ID: 15715079 [TBL] [Abstract][Full Text] [Related]
7. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors. I. The role of tumor suppressor mutations. Carroll SL; Stonecypher MS J Neuropathol Exp Neurol; 2004 Nov; 63(11):1115-23. PubMed ID: 15581179 [TBL] [Abstract][Full Text] [Related]
8. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. Williams KB; Largaespada DA Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955 [TBL] [Abstract][Full Text] [Related]
10. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Rasmussen SA; Overman J; Thomson SA; Colman SD; Abernathy CR; Trimpert RE; Moose R; Virdi G; Roux K; Bauer M; Rojiani AM; Maria BL; Muir D; Wallace MR Genes Chromosomes Cancer; 2000 Aug; 28(4):425-31. PubMed ID: 10862051 [TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR. Lévy P; Vidaud D; Leroy K; Laurendeau I; Wechsler J; Bolasco G; Parfait B; Wolkenstein P; Vidaud M; Bièche I Mol Cancer; 2004 Jul; 3():20. PubMed ID: 15255999 [TBL] [Abstract][Full Text] [Related]
12. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Gottfried ON; Viskochil DH; Couldwell WT Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723 [TBL] [Abstract][Full Text] [Related]
13. How does the Schwann cell lineage form tumors in NF1? Carroll SL; Ratner N Glia; 2008 Nov; 56(14):1590-1605. PubMed ID: 18803326 [TBL] [Abstract][Full Text] [Related]
14. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis. Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515 [TBL] [Abstract][Full Text] [Related]
15. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis. Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083 [TBL] [Abstract][Full Text] [Related]
16. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448 [TBL] [Abstract][Full Text] [Related]